Aurobindo Pharma (AUROPHARMA) — Announcement

📢 Key Event
Aurobindo Pharma's subsidiary to acquire 80% of A1 Biochem Group

🔄 What Changed
80% ownership acquired in A1 Biochem Group

🔮 What's Next
90-120 days to complete acquisition

💡 Investor Takeaway
This adds a US CRO capability to Aurobindo Pharma's API business, expanding its contract research and manufacturing services.

Aurobindo Pharma announced that its subsidiary Apitoria Pharma will acquire 80% ownership of A1 Biochem Group for USD 17 million, adding a US-based CRO with INR 1,024.4 Mn turnover to expand its CRDMO platform and API lifecycle services.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Limited (AUROPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹87,805.59 Cr P/E: 25.3

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"How will the USD 17 million acquisition affect Aurobindo Pharma's valuation?" "What is the revenue contribution of the acquired CRO to Aurobindo Pharma's financials?" "How does the 90-120 day completion timeline impact integration plans?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 23 July 2026

INFY Infosys Limited Financial Results PNBHOUSING PNB Housing Finance Limited Annual Report BPCL Bharat Petroleum Corporation Limited Financial Results CHAMBLFERT Chambal Fertilizers & Chemicals Limited Financial Results SONACOMS Sona BLW Precision Forgings Limited Financial Results TRU TruCap Finance Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.